PinotBio is at the forefront of biotechnology, focusing on innovative cancer therapies. One of their key technologies is the PINOT-ADC™ platform, which represents a next-generation antibody-drug conjugate (ADC) system designed to address the limitations of existing ADC treatments. This platform aims to enhance the efficacy and safety of anticancer drugs by improving the targeted delivery of therapeutic agents directly to cancer cells, thereby minimizing damage to healthy tissues.

In addition to the PINOT-ADC™ platform, PinotBio is developing NTX-301, a best-in-class DNMT1 inhibitor that targets cancer cells through nucleoside-based therapies. This approach is designed to disrupt the cancer cell's ability to proliferate by inhibiting DNA methylation processes. Furthermore, the company is also advancing NTX-101, a first-in-class eye drop formulation intended to lower intraocular pressure and protect the optic nerve, showcasing their commitment to addressing a range of medical needs beyond oncology.

South Korea

We are a biotech company developing new treatments for patients resistant to existing therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC).

Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.

PinotBio

Company Details